What's the Outlook for Inovio Pharmaceuticals Stock?

As of Monday, more than 20 million cases of COVID-19 have been confirmed worldwide, and close to 740,000 deaths have been attributed to it -- and epidemiological experts say both of those official numbers are almost certainly smaller than the real totals. Though it hasn't even been on humanity's radar for nine full months, the coronavirus is projected to cause $9 trillion in economic damage worldwide by the end of the year.

Fortunately, there are now 167 coronavirus vaccine candidates in development. If one or several of them work well, they could save an enormous number of lives and mitigate this economic catastrophe.

One of the leaders in the COVID-19 vaccine race is Inovio Pharmaceuticals (NASDAQ: INO). Last month, I wrote an article about why investors should give Inovio a chance based on the interim phase 1 results of its DNA coronavirus vaccine, INO-4800. The full phase 1 data released Monday showed that its efficacy is much better than expected. Without further ado, let's take a look at why Inovio's outlook will only become brighter from here.

Source Fool.com